Bioterrorism

Milestone reached in the development and manufacture of RiVax

Published in Vaccine Weekly, August 17th, 2005

BioPharma, Inc. (DOR) and a subsidiary of Cambrex Corp. (CBM) announced that they have successfully achieved, ahead of schedule, the first milestone of fermentation and downstream process development in their development and manufacturing agreement for RiVax, DOR's ricin toxin vaccine.

DOR and Cambrex entered into an agreement in January, 2005, under which Cambrex would provide process development and cGMP (current Good Manufacturing Processes) production services for the development and manufacture of clinical quantities of RiVax.

The companies' work has been conducted under a challenge grant totaling $6.4 million awarded to DOR in September, 2004,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2005-08-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry